CAMBRIDGE, Mass., Dec. 28 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today the closing of a previously announced financing
that raised net proceeds to Biopure of approximately $5.8 million. Biopure
sold to institutional and individual investors 10,120,000 new shares of its
common stock and warrants to acquire an additional 10,120,000 new shares. The
price for one share and one warrant was $0.68, and the exercise price of each
warrant is $0.85. This transaction included all of the shares and warrants
granted to the underwriters to cover over-allotments. Dawson James
Securities, Inc. and Noble International Investments, Inc. acted as the
managing underwriters for the public offering.
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. The company is developing Hemopure(R)
[hemoglobin glutamer -- 250 (bovine)], or HBOC-201, for a potential indication
in cardiovascular ischemia and, in collaboration with the U.S. Naval Medical
Research Center, for a potential out-of-hospital trauma indication. The
product is approved in South Africa for treating surgery patients who are
acutely anemic and for eliminating, delaying or reducing allogeneic red blood
cell transfusions in these patients. Hemopure has not been approved for sale
in other jurisdictions, including the United States or the European Union.
Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200
(bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food
and Drug Administration and the European Commission, is indicated for the
treatment of anemia in dogs.
Contact:
Douglas Sayles Herb Lanzet (Investors)
Biopure Corporation H.L. Lanzet Inc.
(617) 234-6826 (212) 888-4570
IR@biopure.com lanzet@aol.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
Company News On-Call:
http://www.prnewswire.com/comp/131224.html
CONTACT:
Douglas Sayles of Biopure Corporation,
+1-617-234-6826, IR@biopure.com; or Herb Lanzet of H.L. Lanzet
Inc., +1-212-888-4570, lanzet@aol.com
|
